BridgeBio Pharma (BBIO) reported a Q2 net loss late Monday of $0.78 per diluted share, narrowing from a loss of $0.95 a year earlier.
Analysts polled by FactSet expected a loss of $0.58.
Revenue for the quarter ended June 30 rose to $243.7 million from $110.6 million a year earlier.
Analysts expected $220.9 million.